Biogen (NASDAQ:BIIB) Updates FY 2026 Earnings Guidance

Biogen (NASDAQ:BIIB) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 15.250-16.250 for the period, compared to the consensus EPS estimate of 14.940. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Jefferies Financial Group upped their price objective on Biogen from $190.00 to $210.00 and gave the company a “buy” rating in a report on Friday, November 28th. The Goldman Sachs Group restated a “buy” rating and set a $225.00 target price on shares of Biogen in a research report on Thursday, January 8th. Hsbc Global Res downgraded Biogen from a “hold” rating to a “moderate sell” rating in a research report on Wednesday, December 10th. Weiss Ratings reissued a “hold (c-)” rating on shares of Biogen in a report on Monday, December 29th. Finally, Mizuho raised their target price on shares of Biogen from $177.00 to $207.00 and gave the company an “outperform” rating in a report on Thursday, January 8th. Eleven equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $192.58.

Biogen Stock Performance

Shares of BIIB stock opened at $185.36 on Friday. The business’s 50-day moving average price is $176.55 and its 200-day moving average price is $156.12. Biogen has a 12 month low of $110.04 and a 12 month high of $190.20. The company has a current ratio of 2.72, a quick ratio of 2.04 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $27.19 billion, a price-to-earnings ratio of 16.90, a PEG ratio of 1.56 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.27. The business had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a return on equity of 14.13% and a net margin of 15.98%.Biogen’s quarterly revenue was down 7.2% on a year-over-year basis. During the same period in the prior year, the business posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities research analysts forecast that Biogen will post 15.83 EPS for the current year.

Insider Transactions at Biogen

In other news, insider Priya Singhal sold 748 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $179.30, for a total value of $134,116.40. Following the transaction, the insider owned 6,271 shares in the company, valued at approximately $1,124,390.30. The trade was a 10.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.18% of the company’s stock.

Hedge Funds Weigh In On Biogen

Several hedge funds and other institutional investors have recently bought and sold shares of the company. CIBC Private Wealth Group LLC grew its holdings in Biogen by 8.1% in the third quarter. CIBC Private Wealth Group LLC now owns 1,189 shares of the biotechnology company’s stock worth $167,000 after purchasing an additional 89 shares during the period. CIBC Bancorp USA Inc. bought a new position in shares of Biogen during the 3rd quarter worth about $3,585,000. Captrust Financial Advisors grew its stake in shares of Biogen by 13.3% in the 3rd quarter. Captrust Financial Advisors now owns 16,532 shares of the biotechnology company’s stock valued at $2,316,000 after buying an additional 1,937 shares during the period. Coldstream Capital Management Inc. increased its position in Biogen by 38.0% in the 3rd quarter. Coldstream Capital Management Inc. now owns 4,480 shares of the biotechnology company’s stock valued at $628,000 after buying an additional 1,234 shares in the last quarter. Finally, Danske Bank A S bought a new stake in Biogen in the 3rd quarter valued at about $6,263,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.